**Motivation**

Blood tests are the gold standard for predicting disease progression in heart failure (HF).

They are also:
- time consuming
- expensive
- painful

What if your smartwatch could tell you when important blood biomarkers change?

**Market research**

NT-proBNP is the single most important measure of HF patient condition and has received a Class I recommendation in HF guidelines.

Our survey of 154 heart failure physicians revealed that despite reviewing patient NT-proBNP levels every 6 months, they preferred much more frequent access to NT-proBNP levels to assess patient condition more effectively.

**Proposed solution**

NT-proBNP tests are expensive and burdensome, requiring a clinic visit. **CardioID** delivers valuable continuous NT-proBNP information to clinicians by combining the collection of non-invasive biomarkers and Bloodless Blood Test algorithms.

**How CardioID works**

HF patients simply wear the **CardioID** smartwatch and periodically interact with the app. The collected digital biomarker data is scanned by Bloodless Blood Test algorithms to identify spikes in NT-proBNP. When a spike is predicted, this is an early sign of a worsening condition, and the clinician is notified to intervene to potentially avoid a hospitalization.

**Clinical research**

**New Bloodless Blood Test algorithms** were trained on GPx’s proprietary database of paired digital and blood biomarkers from HF patients spanning over 15 patient-years.

**Opportunity**

>80% of HF patients lack clinically-validated remote monitoring

5M US patients

$10B TAM

**General Prognostics**

Javier Echenique
Principal Investigator

Sean Matsuoka
Co-investigator

Dr. Andrew Sauer
Clinical Advisor

**Project team**

**Partners**

CentraCare
CentraCare
Jewish Hospital
LEEDS
Saint Luke’s
Saint Luke’s Health System
SonaCare
Sony